Time and Chemotherapy Treatment Trends in the Treatment of Elderly Patients (Age ≥ 70 Years) with Non-small Cell Lung Cancer

Clinical Oncology

Volumn 20, Issue 2, 2008, Pages 142-147

  O'Brien, M E R ^a   Yau, T ^a   Coward, J ^a   Hughes, S ^a   Papadopoulos, P ^a   Popat, S ^a   Norton, A ^a   Ashley, S ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Ageing and cancer; chemotherapy; lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; PLATINUM COMPLEX;

ADVANCED CANCER; AGED; AGING; ARTICLE; CANCER CENTER; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; GENDER; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 39049153827     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2007.11.007     Document Type: Article

References (19)

1. Bunn Jr. P.A., and Lilenbaum R. Chemotherapy for elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 95 (2003) 341-343
2. Cancer Research Campaign. CRC Cancerstats: lung cancer and smoking - UK, 2001.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311 (1995) 899-909
4. Bunn Jr. P.A. Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?. J Clin Oncol 20 (2002) 23S-33S
5. Earle C.C., Venditti L.N., Neumann P.J., et al. Who gets chemotherapy for metastatic lung cancer?. Chest 117 (2000) 1239-1246
6. Percy C., Fritz A., Jack A., Shanmugarathan S., Sobin L., and Parkin D.M. International classification of diseases for oncology (ICD-O) (2000), World Health Organization, Geneva
7. World Health Organization. WHO handbook for reporting results of cancer treatment (1979), World Health Organization, Geneva
8. Kaplan E., and Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
9. Peto R., Pike M., Armitage P., et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patients. II. Analysis and examples. Br J Cancer 35 (1976) 1-39
10. Cox D. Regression models and lifetables. J R Stat Soc 34 (1972) 187-220
11. Yau T., Ashley S., Popat S., et al. Time and chemotherapy treatment trends in the treatment of elderly patients (age >/ = 70 years) with small cell lung cancer. Br J Cancer 94 (2006) 18-21
12. Begg C.B., Cohen J.L., and Ellerton J. Are the elderly predisposed to toxicity from cancer chemotherapy? An investigation using data from the Eastern Cooperative Oncology Group. Cancer Clin Trials 3 (1980) 369-374
13. Earle C.C., Tsai J.S., Gelber R.D., Weinstein M.C., Neumann P.J., and Weeks J.C. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol 19 (2001) 1064-1070
14. Langer C.J., Manola J., Bernardo P., et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 94 (2002) 173-181
15. Billingham L.J., and Cullen M.H. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 12 (2001) 1671-1675
16. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 91 (1999) 66-72
17. Gridelli C., Ardizzoni A., Le Chevalier T., et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 15 3 (2004) 419-426
18. Gibbs D., O'Brien M.E.R., and Polychronis A. Evidence for the palliative treatment of lung cancer. In: Miles A. (Ed). UK Key Advances in Clinical Practice Series 2002 (2002), Aesculapius Medical Press, London
19. Thatcher N., Chang A., Parikh P., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366 (2005) 1527-1537